The ALTER-CAR Project Consortium consist of the Coordinator (Medical University of Warsaw, MUW) and two Partners: Oslo University Hospital (OUH) and the Polish enterprise - Pure Biologics SA.
Dr Magdalena Winiarska from the Department of Immunology, MUW, is the PI of the Project. The PI is supported by WP leaders, Dr Malgorzata Firczuk from the Department of Immunology, MUW as well as Dr Sébastien Wälchli and Dr Else Marit Inderberg from the Cellular Therapy Department, OUH.
Medical University of Warsaw (MUW), one of the oldest and most prominent medical schools in Poland, established a recognized position in research, both in clinical and theoretical medicine. MUW has also fostered its excellence by coordinating the CePT project (from European Structural and Cohesion funds), the biggest biomedical undertaking in Central and Eastern Europe, leading to substantial research infrastructure investments in the years 2007-2013. The scientific excellence and innovation capacity of the MUW team has recently been significantly accelerated by two successfully implemented projects co-financed by EC (BASTION “From Basic to Translational Research in Oncology” 2012–2016, 7th Framework Programme, and STREAM “Strategies towards Excellence in Immuno-Oncology” 2016-2018, Horizon 2020), through hiring new staff, exchange of scientific expertise and investment in cutting edge research equipment. MUW team is concentrated in particular on anti-tumor therapies and strategies to improve immune response against tumors. The team is focused on personalized oncology and the development of diagnostic and therapeutic methods customized to cancer patients’ individual needs. They investigate the pathogenesis of cancer in advanced pre-clinical models, crosstalk between tumor and immune cells, mechanisms of tumor evasion from the immune system, and redox homeostasis in tumor cells in the context of therapeutic targeting.
The ALTER-CAR Project Consortium consist of the Coordinator (Medical University of Warsaw, MUW) and two Partners: Oslo University Hospital (OUH) and the Polish enterprise - Pure Biologics SA.
Dr Magdalena Winiarska from the Department of Immunology, MUW, is the PI of the Project. The PI is supported by WP leaders, Dr Malgorzata Firczuk from the Department of Immunology, MUW as well as Dr Sébastien Wälchli and Dr Else Marit Inderberg from the Cellular Therapy Department, OUH.
Medical University of Warsaw (MUW), one of the oldest and most prominent medical schools in Poland, established a recognized position in research, both in clinical and theoretical medicine. MUW has also fostered its excellence by coordinating the CePT project (from European Structural and Cohesion funds), the biggest biomedical undertaking in Central and Eastern Europe, leading to substantial research infrastructure investments in the years 2007-2013. The scientific excellence and innovation capacity of the MUW team has recently been significantly accelerated by two successfully implemented projects co-financed by EC (BASTION “From Basic to Translational Research in Oncology” 2012–2016, 7th Framework Programme, and STREAM “Strategies towards Excellence in Immuno-Oncology” 2016-2018, Horizon 2020), through hiring new staff, exchange of scientific expertise and investment in cutting edge research equipment. MUW team is concentrated in particular on anti-tumor therapies and strategies to improve immune response against tumors. The team is focused on personalized oncology and the development of diagnostic and therapeutic methods customized to cancer patients’ individual needs. They investigate the pathogenesis of cancer in advanced pre-clinical models, crosstalk between tumor and immune cells, mechanisms of tumor evasion from the immune system, and redox homeostasis in tumor cells in the context of therapeutic targeting.
Oslo University Hospital (OUH), Scandinavia’s largest hospital, supports the late stages of the in-house development of investigator-initiated trials, including operating costs associated with GMP production and patient care/monitoring. The hospital has several national centers of excellence and is closely integrated with the University of Oslo. The Translational Research lab at the Department of Cellular Therapy at OUH, established 5 years ago, has been active in publishing their innovations in major peer-reviewed journals and is a part of different national and international consortiums aiming at proposing immunotherapeutic solutions. This effort has led to the submission of more than 15 patents, the establishment of a biotech (Zelluna Immunotherapy AS) and the first-ever TCR-based clinical protocol in Scandinavia (NCT03431311). For the benefit of the project, the OUH team belongs to the Cellular Therapy Department, a clinical ward validated for human material (peripheral blood/bone marrow) isolation and possesses Nothern Europe's largest cleanroom. The OUH team is located at the Oslo Cancer Cluster incubator (OCCi), which is an ideal ecosystem for meeting business partners and collaborating biotechs.
Pure Biologics S.A. [Inc.], founded in 2010, is a Warsaw Stock Exchange-listed preclinical-stage biopharmaceutical company developing innovative biological drugs and therapeutic devices for medical use. The company specializes in protein engineering and efficient production of difficult-to-express proteins, protein biophysics and analytics, as well as methods for the discovery of new antibodies and aptamers by leveraging its two proprietary technological platforms based on in vitro selection principles. The company’s technologies are supported by extensive internal R&D activities and unique in-house expertise and employees' know-how. Currently, there are four drug discovery programs and two medical devices in development. Pure Biologics is a Polish market leader in the technology of in vitro selection of antibodies and aptamers for medical applications and one of a few commercial entities in this area of Europe, making the company poised to further strengthen its market position and build value. Combinatorial in vitro selection is an efficient and cost-effective way to obtain bioactive molecules (antibodies and aptamers) for the selected molecular target(s). This is both the basis for the internal drug discovery efforts as well as technology that can be leveraged to provide external contract research services.
, Scandinavia’s largest hospital, supports the late stages of the in-house development of investigator-initiated trials, including operating costs associated with GMP production and patient care/monitoring. The hospital has several national centers of excellence and is closely integrated with the University of Oslo. The Translational Research lab at the Department of Cellular Therapy at OUH, established 5 years ago, has been active in publishing their innovations in major peer-reviewed journals and is a part of different national and international consortiums aiming at proposing immunotherapeutic solutions. This effort has led to the submission of more than 15 patents, the establishment of a biotech (Zelluna Immunotherapy AS) and the first-ever TCR-based clinical protocol in Scandinavia (NCT03431311). For the benefit of the project, the OUH team belongs to the Cellular Therapy Department, a clinical ward validated for human material (peripheral blood/bone marrow) isolation and possesses Nothern Europe's largest cleanroom. The OUH team is located at the Oslo Cancer Cluster incubator (OCCi), which is an ideal ecosystem for meeting business partners and collaborating biotechs.
Pure Biologics S.A. [Inc.], founded in 2010, is a Warsaw Stock Exchange-listed preclinical-stage biopharmaceutical company developing innovative biological drugs and therapeutic devices for medical use. The company specializes in protein engineering and efficient production of difficult-to-express proteins, protein biophysics and analytics, as well as methods for the discovery of new antibodies and aptamers by leveraging its two proprietary technological platforms based on in vitro selection principles. The company’s technologies are supported by extensive internal R&D activities and unique in-house expertise and employees' know-how. Currently, there are four drug discovery programs and two medical devices in development. Pure Biologics is a Polish market leader in the technology of in vitro selection of antibodies and aptamers for medical applications and one of a few commercial entities in this area of Europe, making the company poised to further strengthen its market position and build value. Combinatorial in vitro selection is an efficient and cost-effective way to obtain bioactive molecules (antibodies and aptamers) for the selected molecular target(s). This is both the basis for the internal drug discovery efforts as well as technology that can be leveraged to provide external contract research services.